Category: Clinical Trials

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

Posted on | Posted on John Murphy | Leave a Comment on More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

Authors: Sandra Lopez-Leon, Talia Wegman-Ostrosky, Carol Perelman, Rosalinda Sepulveda, Paulina A. ebolledo, Angelica Cuapio & Sonia Villapol Abstract COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systematic review and meta-analysis aims to identify studies assessing the long-term effects of COVID-19. LitCOVID and Embase were searched to identify articles with original data […]

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Authors: Pierre Kory, MD,1,*Gianfranco Umberto Meduri, MD,2Joseph Varon, MD,3Jose Iglesias, DO,4 and Paul E. Marik, MD5 Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within […]

Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

Posted on | Posted on John Murphy | Leave a Comment on Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

Authors: Jonathan P Rogers1,2, Cameron J Watson3, et.al Abstract There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2. In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and estimate point prevalences for neurological and neuropsychiatric manifestations. We searched MEDLINE, Embase, PsycINFO and CINAHL up to […]

India’s Ivermectin Blackout

Posted on | Posted on John Murphy | Leave a Comment on India’s Ivermectin Blackout

Authors: Authored by Justus R Hope, MD. via TheDesertReview.com, Ivermectin Wins in India News of India’s defeat of the Delta variant should be common knowledge. It is just about as obvious as the nose on one’s face. It is so clear when one looks at the graphs that no one can deny it. Yet, for […]

Ivermectin for COVID-19: real-time meta analysis of 63 studies

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin for COVID-19: real-time meta analysis of 63 studies

Authors: Covid Analysis, Aug 12, 2021, Version 109 — twitter personality response, added Together Trial (V1 Nov 26, 2020) •Meta analysis using the most serious outcome reported shows 73% and 86% improvement for early treatment and prophylaxis (RR 0.27 [0.16-0.44] and 0.14 [0.08-0.25]), with similar results after exclusion based sensitivity analysis, restriction to peer-reviewed studies, restriction to serious outcomes, and restriction to Randomized Controlled Trials.•61% and […]

Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns

Posted on | Posted on John Murphy | Leave a Comment on Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns

The preprint endorsing ivermectin as a coronavirus therapy has been widely cited, but independent researchers find glaring discrepancies in the data Authors: Melissa Davey The efficacy of a drug being promoted by rightwing figures worldwide for treating Covid-19 is in serious doubt after a major study suggesting the treatment is effective against the virus was […]

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Authors: Fatemeh Heidary 1, Reza Gharebaghi 2 3 Abstract Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies […]

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Posted on | Posted on John Murphy | Leave a Comment on A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Authors: Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6 Abstract Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial […]

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Posted on | Posted on John Murphy | Leave a Comment on Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Authors: Andrew Bryant, MSc,1,* Theresa A. Lawrie, MBBCh, PhD,2 Therese Dowswell, PhD,2 Edmund J. Fordham, PhD,2 Scott Mitchell, MBChB, MRCS,3 Sarah R. Hill, PhD,1 and Tony C. Tham, MD, FRCP4 Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed […]

Critics Fault Henry Ford Hydroxychloroquine Study Methodology, Conclusion

Posted on | Posted on John Murphy | Leave a Comment on Critics Fault Henry Ford Hydroxychloroquine Study Methodology, Conclusion

Authors: by Alex McLenon | July 15, 2020 One critic says the study, which found the drug led to fewer COVID-19 deaths, did not used a randomized trial and patients not administered the drug were more likely to die anyway. A recent Henry Ford Health System study finding COVID-19 patients treated with hydroxycloroquine were less likely to die from the virus is drawing skepticism […]